News zum Sektor Gesundheit aus Island

 

Announcement no. 11/2026 24 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, February 24, 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the final agenda and proposals for the Company's 2026 Annual General Meeting, which will be held on Tuesday 10 March 2026 at 9:00 AM (GMT) at the Company's headquarters at Grjótháls 1-5, Reykjavík, Iceland. The final agenda can be found enclosed with this announcement. No changes have been made to the previously announced agenda and proposals. Further information...

Announcement no. 10/2026 23 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, 23 February 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 16 February to 20 February 2026 Embla Medical has acquired 28,883 shares under the Program at the average price of DKK 30.16. Following the transactions below, the Company holds 2,949,988 shares, corresponding to 0.69%...

Announcement no. 9/2026 17 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, February 17, 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that Embla Medical's Annual General Meeting will be held on Tuesday 10 March 2026 at 9:00 AM (GMT) at the Company's headquarters at Grjótháls 1-5, Reykjavík, Iceland. The convocation can be found enclosed to this announcement and includes the proposed agenda for the Annual General Meeting and information on shareholders' participation and registration, shareholders'...

Announcement no. 8/2026 16 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, 16 February 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 9 February to 13 February 2026 Embla Medical has acquired 25,486 shares under the Program at the average price of DKK 30.89. Following the transactions below, the Company holds 2,921,105 shares, corresponding to 0.68% of...

Announcement no. 7/2026 9 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, 9 February 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 2 February to 6 February 2026 Embla Medical has acquired 43,000 shares under the Program at the average price of DKK 31.31. Following the transactions below, the Company holds 2,895,619 shares, corresponding to 0.67% of...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: "We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency......

Announcement no. 6/2026 3 February 2025 Embla Medical hf: 2025 Annual Report The full Annual report including Remuneration and Governance Reports can be downloaded from our website https://emblamedical.com/investor-relations/annual-report Letter from our President and CEO Sveinn Sölvason 2025 was a year of meaningful progress for Embla Medical. Across geographies and patient care settings, the need for our solutions remains as strong as ever, and once again, our teams delivered with focus and purpose.  We achieved 6% organic growth driven by strong performance in...

Announcement no. 5/2026 Interim Report Q4 and Full Year 2025 Sveinn Sölvason, President and CEO, comments: “We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025. Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish to the...

Announcement no. 4/2026 2 February 2026 Reykjavik, Iceland/Copenhagen, Denmark, 2 February 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 26 January to 30 January 2026 Embla Medical has acquired 30,584 shares under the Program at the average price of DKK 31.78. Following the transactions below, the Company holds 2,852,619 shares, corresponding to 0.66% of...

Announcement no. 3/2026 26 January 2026 Reykjavik, Iceland/Copenhagen, Denmark, 26 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 19 January to 23 January 2026 Embla Medical has acquired 58,333 shares under the Program at the average price of DKK 32.05. Following the transactions below, the Company holds 2,822,035 shares, corresponding to 0.66% of...

Announcement no. 2/2026 19 January 2026 Reykjavik, Iceland/Copenhagen, Denmark, 19 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 12 January to 16 January 2026 Embla Medical has acquired 49,106 shares under the Program at the average price of DKK 32.50. Following the transactions below, the Company holds 2,763,702 shares, corresponding to 0.64% of...

Announcement no. 1/2026 12 January 2026 Reykjavik, Iceland/Copenhagen, Denmark, 12 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 5 January to 9 January 2026 Embla Medical has acquired 41,000 shares under the Program at the average price of DKK 32.37. Following the transactions below, the Company holds 2,709,596 shares, corresponding to 0.63% of the...

Reykjavik, Iceland/Copenhagen, Denmark, 9 January 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q4/FY 2025 Report on February 3, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate...

Announcement no. 61/2025 23 December 2025 Reykjavik, Iceland/Copenhagen, Denmark, December 23, 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the Company has decided to initiate a new share buyback program (the “Program”) on Monday, 5 January 2026. The Program will be carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission's delegated regulation 2016/1052. The purpose of the Program is to reduce the Company's...

Announcement no. 60/2025 23 December 2025 Reykjavik, Iceland/Copenhagen, Denmark, 23 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the completion of the share buyback program, which was announced in Company Announcement no. 3/2025 dated 7 February 2025. Following are the last transactions carried out under the current share buyback program. Transaction No. of Avg. purchase price in DKK Transaction value in DKK date shares 22 December 5,000 33.70...

Announcement no. 59/2025 22 December 2025 Reykjavik, Iceland/Copenhagen, Denmark, 22 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025. During the period 15 December to 19 December 2025 Embla Medical has acquired 10,400 shares under the Program at the average price of DKK 33.20. Following the transactions below, the Company holds 2,668,596 shares, corresponding to 0.62% of...

Announcement no. 58/2025 15 December 2025 Reykjavik, Iceland/Copenhagen, Denmark, 15 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025. During the period 8 December to 12 December 2025 Embla Medical has acquired 45,275 shares under the Program at the average price of DKK 36.34. Following the transactions below, the Company holds 2,658,196 shares, corresponding to 0.62% of...

Announcement no. 57/2025 Reykjavik, Iceland/Copenhagen, Denmark, December 12, 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today published its financial calendar for 2026. Financial Calendar 2026 3 February 2026                         Interim Report Q4 2025/2025 Annual Report 10 March 2026                           2026 Annual General Meeting 28 April 2026                              Interim Report Q1 2026 21 July 2026                              Interim Report Q2 2026 20 October 2026...

Announcement no. 56/2025 8 December 2025 Reykjavik, Iceland/Copenhagen, Denmark, 8 December 2025. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 3/2025 dated 7 February 2025. During the period 1 December to 5 December 2025 Embla Medical has acquired 30,000 shares under the Program at the average price of DKK 36.90. Following the transactions below, the Company holds 2,618,929 shares, corresponding to 0.61% of the...